Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. The company is headquartered in Cambridge, Massachusetts. Show more

275 WYMAN STREET, WALTHAM, MA, UNITED STATES, 02451, Waltham, MA, 02451, USA

https://www.cogentbio.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

5.608B

52 Wk Range

$3.72 - $43.73

Previous Close

$36.72

Open

$36.84

Volume

1,046,963

Day Range

$36.30 - $37.60

Enterprise Value

5.384B

Cash

125.3M

Avg Qtr Burn

-64.29M

Insider Ownership

0.28%

Institutional Own.

99.89%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Bezuclastinib (CGT9486) (KIT exon 17 inhibitor) Details Nonadvanced systemic mastocytosis (NonAdvSM)	NDA Acceptance for review	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bezuclastinib (CGT9486) (KIT exon 17 inhibitor) Details Advanced systemic mastocytosis (AdvSM)	NDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bezuclastinib (CGT9486) (KIT exon 17 inhibitor) + Sunitinib Details Cancer, Gastrointestinal stromal tumors	NDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bezuclastinib (CGT9486) (KIT exon 17 inhibitor) + Sunitinib Details First-Line Gastrointestinal Stromal Tumors With Exon 9 Mutations	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CGT4255 / CNS-penetrant ErbB2 program Details Solid tumor/s	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CGT4859 (FGFR2 inhibitor) Details Advanced cholangiocarcinoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.